Revlimid (lenalidomide)

March 10, 2020March 10, 2020

Tafasitamab Plus Revlimid Granted FDA Priority Review for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted priority review to MorphoSys’ application seeking approval of its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat people with relapsed ... Read more

January 2, 2020January 2, 2020

Revlimid-Rituximab Combo Approved in Europe for Previously Treated Follicular Lymphoma

News

The European Commission has approved Bristol-Myers Squibb‘s Revlimid (lenalidomide) in combination with rituximab to treat adults with follicular lymphoma who are no longer responding to other therapies. The combination is the first chemotherapy-free treatment ... Read more

December 5, 2019

CHMP Favors Revlimid-Rituximab Combo for Advanced Follicular Lymphoma Patients in EU

News

A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned ... Read more

September 6, 2019

Gazyva-Revlimid Effective for Certain Patients with Relapsed or Refractory Follicular Lymphoma, Trial Suggests

News

A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 ... Read more

August 8, 2018

Gazyva-Revlimid Combo Shows Promise for Follicular Lymphoma Patients in Clinical Trial

News

Gazyva (obinutuzumab) with Revlimid (lenalidomide) — a combination called Galen — is a potentially safe and effective treatment for relapsed or refractory follicular lymphoma, with over 60% of patients responding to treatment, ... Read more

January 18, 2017

Three-Drug Combination Shows Promise for Treating Mantle Cell Lymphoma

News

A combination of Rituxan (rituximab), Revlimid (lenalidomide), and Bendeka (bendamustine) (R2B) may be a viable option for treating relapsed or treatment-resistant mantle cell lymphoma, a study suggested. A Phase 2 ... Read more